Hyperkalaemia: aetiology, epidemiology, and clinical significance

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Potassium homeostasis disturbances are prevalent in heart failure (HF) patients.
• Common risk factors for hyperkalemia in HF include diabetes, hypertension, and chronic kidney disease.
• Renin-angiotensin-aldosterone system (RAAS) inhibitors increase hyperkalemia risk.

Purpose of the Study:

• To review the epidemiology of potassium disturbances in HF.
• To discuss the causes (aetiology) of hyperkalemia in heart failure.
• To outline the clinical consequences of potassium imbalances in HF patients.

Main Methods:

• Literature review of studies on potassium homeostasis in heart failure.
• Analysis of risk factors and clinical outcomes associated with hyperkalemia.
• Discussion of the impact of hyperkalemia on RAAS inhibitor therapy.

Main Results:

• Hyperkalemia is frequent in HF and linked to adverse outcomes.
• Hyperkalemia often necessitates RAAS inhibitor dose reduction or discontinuation.
• The link between hyperkalemia and mortality in HF is complex and debated.

Conclusions:

• Potassium disturbances significantly impact HF management and outcomes.
• Addressing hyperkalemia is crucial for optimizing RAAS inhibitor therapy in HF.
• Further research is needed to clarify the mortality association and management strategies.